Abstract | Osteoarthritis (OA) is the most prevalent joint disease, but neither preventive measures nor diseasemodifying drugs are available and a continuing need exists for safe and effective symptom-modifying therapies. Clinical trials of candidate disease-modifying OA drugs in patients with established or advanced disease have not demonstrated their efficacy, but these failed trials have motivated investigation into the mechanisms that maintain joint health. The enhancement of such mechanisms could be a novel approach to reducing the risk of OA. Aging is one of the most important risk factors for OA; however, aging of joint cartilage is a process that is distinct from the subsequent cartilage changes that develop following the onset of OA. This Review focuses on the mechanisms that maintain cell and tissue homeostasis, and how these mechanisms fail during the aging process. Autophagy is a cellular homeostasis mechanism for the removal of dysfunctional organelles and macromolecules. Defective autophagy is involved in the pathogenesis of aging-related diseases and recent observations indicate that this process is compromised in aging cartilage. Augmentation of homeostasis mechanisms is discussed as a novel avenue to delay joint aging and reduce OA risk.
Introduction
Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and affects more than 30 million Americans. As the US population ages, the number of patients with OA is projected to double by 2030. 1 In 2002, approximately 500,000 hip and knee replacements were performed in the USA (the majority for OA), and this number is expected to double by 2015. 2, 3 OA causes more lower-extremity dys function and related complications than any other dis ease; it also compromises the overall health, quality of life, and life expectancy of affected individuals. 4, 5 No disease-modifying OA drugs (DMOADs) are currently available. 6 A large number of drug candi dates have been tested in clinical trials but either failed to show effi cacy or were associated with adverse events. 7 The pharmaco logical management of OA is, therefore, limited to agents that relieve pain and to the complementary and alternative medicines used by many patients with OA, which incur expenses similar to those of tradition al pharmaceuticals. 8, 9 Substantial progress has been made in identifying the central pathogenetic pathways mediating the progressive joint destruction that occurs in established OA ( Figure 1) . [10] [11] [12] OA is clearly a heterogeneous dis ease, with differences in specific initiating mechanisms and in risk factor profiles between patient sub populations. Degradation of the articular cartilage is central to OA pathogenesis, but other joint tissues are invariably affected.
The temporal and mechanistic relationships of changes in the different tissue compartments, in particular between bone and cartilage, are subjects of debate. 13 Joint inflammation of varying severity is present in patients with OA.
14 Lesions in ligaments and menisci can develop at the same time as cartilage lesions, whereas primary traumatic injuries to menisci or ligaments leads to secondary cartilage degradation and OA in at least 50% of cases. 15 Pathways of cartilage destruction in OA include cell death, cell activation and abnormal differentiation of remaining cartilage cells, degradation of the extra cellular matrix, and production of inflammatory mediators ( Figure 1 ). Within each of these pathways, critical signaling and effector molecules have been identified. [10] [11] [12] Targeting these pathways pharmacologically has been successful in reducing the severity of cartilage destruction in animal models of arthritis. Candidate drugs that have shown disease-modifying activities in such models include inhibitors of matrix-degrading enzymes (matrix metalloproteinases, aggrecanases), inhibitors of inflammatory mediators (IL-1, TNF, cy clo-oxygenase-2, inducible nitric oxide synthase), growth factors (bone morphogenic protein 7, fibroblast growth factor 18), drugs targeting bone remodel ing (bisphosphonates, calcitonin, osteoprotegerin), kinase inhibi tors, lubricants (hyaluronic acid, proteo glycan 4), and vitamins. 16, 17 Nutraceuticals such as gluco samine, chondroitin sulfate, and avocado extracts have also shown efficacy in these models. 18, 19 The reason for the failure of this large number of candidate treatments to translate into clinical applications is unknown, but potential explanations focus on OA pathogenesis pathways and molecules targeted, the predictive value of animal models, and the selection of endpoints and patients for clinical trials. 20 New perspectives discussed here include mecha nisms that maintain joint health, and how such mecha nisms might deteriorate with normal aging and in individuals at risk of early onset of OA. We propose that the augmentation of homeostasis mechanisms could serve as a novel approach to maintaining joint health and decreasing the risk of developing OA.
Cartilage changes in aging and OA
Joint health is dependent on normal structure and function of all joint tissues, including cartilage, subchondral bone, ligaments, menisci, synovia, and synovial fluid. OA is a whole-joint disorder manifested by loss of joint Importantly, these changes in chondrocytes differ in many respects from those seen in OA, which is characterized by cell activation with increased proliferation and gene expression. [21] [22] [23] [24] [25] [26] Disruption of the articular cartilage superficial zone is now recognized to be a key triggering event for the chronic and progressive extracellular matrix remodeling process that ultimately manifests as OA. 23, [27] [28] [29] [30] [31] [32] [33] [34] Given this critical role of the superficial zone, this Review focuses on mechanisms that are required for superficial zone homeostasis and the earliest events that lead to its disruption.
Role of superficial zone in normal cartilage
The principal functions of articular cartilage are to provide a surface for the movement of two articulating bones and to dissipate mechanical load. 35 These bio mechanical functions are enabled by the unique structure of the cartilage superficial zone, which spans the first 10-20% of full-thickness articular cartilage and forms a fluid-tissue interface in the synovial cavity. During normal joint use, the superficial zone is exposed to compressive and shear forces; these normal levels of mecha ni cal stress do not lead to wear because of the unique com position and properties of superficial zone cartilage. The outermost layer of molecules on the cartilage surface contains the joint lubricants proteoglycan 4 (also known as superficial zone proteoglycan or lubricin), hyaluronic acid, and phospholipids. In cartilage, the production of proteoglycan 4 is a specific function of cells in the superficial zone but not cells in the middle and deep zones. The repertoire of superficial zone chondrocyte proteins includes several other secreted and cellular proteins that are distinct from those produced by cells in the middle and deep zones. 36, 37 An important feature of the superficial zone is that it contains most of the mesenchymal stem cells (MSCs) that are present in adult cartilage. [38] [39] [40] Conceptually, the presence of MSCs would endow the superficial zone with the capacity for self-renewal, which might be required to sustain its integrity under exposure to mechanical stress.
Superficial zone cartilage in aging and OA The superficial zone can be compromised by excessive mechanical stress, either acute or chronic, and by aging-related declines in cell function or viability. Results from in vitro and animal models demonstrate that the super ficial zone is more susceptible to damage induced by mechanical stress than other cartilage zones. 41 Once Cartilage degradation is influenced by systemic risk factors (genetic risk, obesity), joint instability or malalignment, and changes in other joint tissues. In established OA, cartilage lesion progression is mediated through the action of biochemical stimuli and mechanical stress on chondrocytes, which have altered gene expression patterns due to aging-related intracellular changes. Effector mechanisms activated in the chondrocyte include production of inflammatory mediators, extracellular matrix degradation, abnormal differentiation, and cell death. Abbreviation: OA, osteoarthritis.
the superficial zone is disrupted, cartilage cells are activated, and-through the production of matrix-degrading enzymes-lesions expand in depth and diameter. These lesions subsequently cause joint inflammation, pain, and joint dysfunction, the major manifestations of OA. Thus, understanding the mechanisms that maintain superficial zone integrity, and the causes of their failure, will identify approaches to maintain joint health. Loss of cells, via apoptosis and other types of cell death, are among the major changes that occur in the superficial zone because of aging or exposure to mechanical stress. The number of chondrocytes near the articular surface of macroscopically normal cartilage from human femoral condyles decreases by ~50% between the ages of 20 and 90 years, 34 a decrease that is associated with biomechanic al softening of cartilage. 42 Findings presented during the past 2 years have advanced concepts of how superficial zone cell survival is maintained, and how the unique differentiation status of superficial zone cells is regulated ( Figure 2 ). The chromatin protein high mobility group protein B2 (HMGB2) is uniquely expressed in superficial zone cells in human and animal cartilage. 43 With increasing age, the number of cells expressing HMGB2 declines, and proteoglycan 4 expression is reduced. Mice deficient in the gene encoding HMGB2 show increased super ficial zone cell death and reduced proteoglycan 4 production. The onset of degenerative changes in the superficial zone occurs at an earlier age in these genetically modified mice and is followed by a more severe OA-like joint pathology than observed in wild-type mice. 43 The major functions of HMGB2 are to support superficial zone cell survival through interactions with β-catenin signaling, 44 and to control the unique gene expression profile and differentiation status of superficial zone cells, including MSCs ( Figure 2 ).
Mechanisms of cartilage homeostasis
Cartilage biomechanical function is dependent on normal tissue structure, which is maintained by the pres ence of an appropriate number of cells with normal bio synthetic function ( Figure 3) . Mechanical loading within a physiological range also has a role in supporting carti lage homeo stasis. Cellular homeostasis is dependent on intracellular mechanisms that maintain functional organelles and macromolecules that are required for cell survival and normal biosynthetic function. In tissues with a high rate of cell turnover, cellular constituents are continuously renewed. By contrast, cartilage is a post mitotic tissue with very low, barely detectable rates of cell replication. Cells in such tissues depend on autophagy as a principal mechanism for the removal of damaged and dysfunctional organelles and macromolecules. 45 The unfolded protein response (UPR; also called endo plasmic reticulum [ER] stress response) is a related mechanism that assures normal protein folding during protein synthesis in the ER. [46] [47] [48] [49] In cells exposed to ER stress, activation of the UPR can initiate autophagy to remove misfolded proteins, thus promoting cell survival. 50 The consequences of abnormal autophagy and UPR are deficiencies or dysfunctions in secreted molecules, inflammation, and cell death (Box 1). The importance of these control mechanisms is clearly demonstrated by observations that their dysfunction accelerates the development of aging-related diseases, 51, 52 which has led to the identification of new therapeutic targets for these diseases. 53, 54 Autophagy is a lysosomal degradation pathway that is essential for survival, differentiation, development, and homeostasis. 55 However, in certain physiological and pathological conditions, it can lead to a form of cell death that is characterized by cytoplasmic vacuola tion, termed type II programmed cell death or 'cell death by autophagy' . [56] [57] [58] [59] [60] Autophagy is induced by stressors such as nutrient and energy deprivation, reactive oxygen species or hypoxia. The morphological hallmark of autophagy is the formation of the sequestering vesicle, the auto phagosome. The molecular components of the autophagy machinery, the proteins encoded by Atg genes, were first identified in yeast; corresponding homologs have since been identified in higher eukaryotes. Among the Atg genes, ATG1, ATG6, ATG8 (ULK1, BECN1, and MAP1LC3B in humans, respectively), and ATG5 are four major regulators of the autophagy pathway in yeast and other organisms. In humans, a key regulator of autophagy initiation is the mammalian target of rapamycin complex 1 (mTORC1) (Figure 4 ). High nutrient availability leads to activation of mTORC1 to stimulate protein synthesis through activation of ribosomal protein S6 kinase β-1 and the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). At the same time, mTORC1 inhibits autophagy by phosphorylating serine/ threonine-protein kinase unc-51-like kinase 1 (ULK1).
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ULK1 transduces pro-autophagic signals to initiate autophagosome formation. 49 Activation of ULK1 through inhibition of mTORC1 stabilizes the formation of a com plex of mTORC1 with 200 kDa FAK family kinaseinteracting protein (FIP200) and autophagy-related protein (ATG) 13, and leads to subcellular redistribution to initiate the formation of autophagosomes. First, an iso lated double-membrane structure or initial sequestering compartment (phagophore) is formed (nucleation). This process is driven by production of phosphatidylinositol 3-phosphate-enriched membrane domains, resulting from activation of a complex of beclin-1 with class III PI3 kinase on vesicles, which acts as a nucleus for recruitment of further proteins involved in autophagosome production. 62, 63 Recognition of the ma terial to be autophagocytosed occurs during this process. Next, the phagophore undergoes growth and closure to form the autophagosome, a process that is driven by two ubiquitin-related conjugation systems, the conjugation of phosphatidylethanolamine with microtubule-associated protein 1A/1B-light chain 3 (LC3)-I (cytosolic form of LC3), resulting in the formation of the autophagy marker LC3-II (membrane bound form of LC3), and ATG12-ATG5 conjugation. The autophagosome, which is enclosed by double-layered or multilayered membranes, then fuses with the lysosome. Finally, the enclosed cargo Cartilage homeostasis depends on normal extracellular matrix structure, which is maintained by a balance between rates of synthesis and degradation. Cellular homeostasis requires defense mechanisms that protect cells against oxidants and prevent DNA mutations and telomeric DNA damage. The UPR is activated upon detection of unfolded or misfolded proteins and prevents protein dysfunction and aggregation. The process of autophagy has roles in nutrient and energy homeostasis, and is essential for the removal of dysfunctional cellular organelles and macromolecules. Normal functioning of cellular homeostasis mechanisms maintains a physiological rate of cell replication, retention of adult stem cell populations and normal differentiation. Abbreviation: UPR, unfolded protein response. is degraded by lysosomal enzymes, and the constituents are released and reutilized. Autophagy occurs at low basal levels in mammalian cells, and performs homeostatic functions such as facilitating the turnover of proteins and organelles. 64 Loss of this basal function leads to the deposition of a ggregationprone proteins that stimulate production of reactive oxygen species (ROS). Both ROS accumulation 65 and mTORC1 activation 66 are associated with accelerated aging and the development of aging-associated pathologies. Conversely, reduction of ROS levels by antioxidants or as a result of mTORC1 inhibition causes an extension of lifespan. 67 Autophagy also prevents the accumulation of defective mitochondria that produce high levels of ROS. 45 By controlling these detrimental processes, autophagy has an important anti-aging function and reduces agingassociated cell death, dysfunction, and disease. Genetic studies in model organisms support the importance of autophagy in physiological and pathological events. Loss of autophagy genes leads to neurodegeneration, cardiomyopathies, abnormalities in skeletal development, and death, and is associated with the accumulation of cy toplasmic protein aggregates. 68 In articular cartilage, a postmitotic tissue characterized by a very low rate of cell turnover, 69 autophagy would seem to be essential to the maintenance of normal cell function and survival as it removes dysfunctional organelles, including mitochondria, peroxisomes, and ribosomes, and aggregate-prone or misfolded proteins. 70 Mitochondrial dysfunction has been demonstrated in OA and is associated with excessive production of ROS. 71 However, whereas autophagy changes with aging in various models and tissues, 72 this process has not been sufficiently investigated in articular cartilage.
Box 1 | Consequences of autophagy and UPR

Normal autophagy and UPR
Autophagy is a constitutively active and seemingly protective process for the maintenance of articular cartilage homeostasis. 73 The cartilage superficial zone shows the strongest expression of all autophagy regulators examined thus far, including ULK1, Beclin-1, and LC3. Human OA and aging-related and surgically-induced OA in mice are associated with a reduction and loss of ULK1, Beclin-1, and LC3 expression in articular cartilage. 73 Furthermore, the reduction of these key regulators of autophagy is mTORC1 is the central regulator of autophagy as it inhibits ULK1, the initiator of autophagy. mTOR within mTORC1 integrates input from growth factor pathways, and from mechanisms that sense hypoxia, energy and nutrient status. When active, mTOR forms a complex with ULK1, FIP200 and ATG13, and phosphorylates ULK1 and ATG13 to repress autophagy. Nutrient deficiency, low-energy-status or rapamycin cause mTOR inhibition, ULK1 dissociation and initiation of the autophagy cascade. First, an isolated double-membrane structure (phagophore) is formed, driven by production of PI(3)P-enriched membrane domains by beclin-1 associated class III PI3K on vesicles. Next, the phagophore undergoes elongation and closure, processes driven by two ubiquitin-related conjugation systems, the conjugation of LC3-I to phosphatidylethanolamine (resulting in the formation of the autophagy marker LC3-II) and ATG12-ATG5 conjugation. The autophagosome, which is enclosed by double-layered or multilayered membranes, then fuses with the lysosome. Finally, the enclosed cargo is degraded, followed by the release and reutilization of the constituents. Abbreviations: AMPK, 5'-AMP-activated protein kinase; ATG, autophagy-related protein; FIP200, 200 kDa FAK family kinase interacting protein; LC3, microtubule-associated protein 1A/1B-light chain 3; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; PI(3)P , phosphatidylinositol 3-phosphate; PI3K, phosphatidylinositol-3 kinase; ULK1, unc-51-like kinase 1.
accompanied by increased apoptosis. These observations in cartilage are consistent with the notion that the basal autophagic activity decreases with age, thus contributing to the accumulation of damaged macromolecules and increased susceptibility to aging-related OA. 74 
Enhancing homeostasis mechanisms
Changes in cartilage cells and extracellular matrix are an inevitable consequence of aging, but not all older individuals are diagnosed with OA or have typical OA pathology at autopsy. These aging-related changes have been described as 'normal aging' , but this description does not imply normal tissue function and, importantly, these changes have adverse consequences as they increase the risk of OA. The onset of aging-related changes in human cartilage typically begins in the fifth decade, 33 and with progression can ultimately lead to overt OA. In combination with other risk factors, such as acute or chronic mechanical injury, obesity, or joint mal alignment, aging-related changes in cartilage could lead to an earlier onset or the development of a more severe form of OA. Decelerating aging-related changes, therefore, could reduce the risk of early-onset OA.
The principal aging-related changes in cartilage are similar to those in other tissues and include compromised cellular biosynthetic capacity and cell death. The progressive accumulation of damaged macromolecules and organelles in somatic cells, which leads to the decreased ability of cells to function normally and survive, has been identified as a common mechanism in various tissues, and abnormal protein aggregation and formation of characteristic pathological structures are central features of aging-related diseases. 75 Autophagy and the UPR, which maintain normal cell function and survival, are regulated by signaling pathways that control longevity in model organisms such as Caenorhabditis elegans, Drosophila melanogaster and mice. Recent evidence indicates that autophagy is required for lifespan extension in various model organisms, and that numerous autophagy-related genes or proteins are directly regulated by longevity pathways. 76 The mechanisms by which autophagy is lost with aging -for example, reduced expression of autophagy proteins or failure of lysosomal hydrolases, 77, 78 -result in an increase of toxic protein products and slow clearance of auto phagosomes. 79 The effects of oxidative stress on the insulin receptor signaling pathway seem to have a critical role in the decreased activation of autophagy observed in aged organisms. 80 The signaling network involving longevity factors sirtuin-1 (SIRT1), mammalian target of rapamycin (mTOR), forkhead family O subclass transcription factor 3 (FoxO3), nuclear factor-κB (NFκB), and p53 regulates autophagy. mTOR and NFκB repress the autophagy pathway under input signals of stress and inflammation, whereas autophagy is enhanced by SIRT1 (a stress-resistance and longevity factor), and FoxO3 (a major regulator of cellular metabolism, proliferation, and oxidant stress resistance). 81 Conceptually, decelerating specific aging effects that increase the risk of disease development could be accomplished by intervening at a critical level in the regulation of autophagy or by modulating general longevity pathways. Interventions that have the potential to delay aging-related dysfunction and extend lifespan are at the first stage of in vivo testing in model organisms. 82 Candidate interventions in diverse chemical and functional categories have been considered, including pharmaceuticals, nutriceuticals, hormones, vitamins, antioxidants, chelating agents, and extracts from various natural materials. Caloric restriction has also been shown to extend lifespan in various species, including mice, rats, and dogs. 83 Lifespan extension in dogs was associated with reduced severity of hip OA. 84 Discussion continues regarding the mechanisms that mediate the effects of caloric restriction, but attenuation of oxidative damage and changes in insulin-like signaling are likely to be important. Autophagy is required for the beneficial effects of caloric restriction in some models. 85 A program that tests interventions for lifespan extension, coordinated by the NIH National Institute on Aging, is currently evaluating more than 10 such agents in populations of genetically heterogeneous mice. 86 Results published thus far indicate that the lipoxy genase inhibitor nordihydroguaiaretic acid, aspirin, 87 and rapamycin, 88 but not resveratrol or simvastatin, 89 prolong lifespan. The study of rapamycin is remarkable as it demon strated the extension of lifespan by 28% in male mice and by 38% in female mice, even when treatment was initiated as late as age 20 months, which corres ponds to approximately age 60 in humans. Although these observations are encouraging, it is unknown whether therapies that prolong lifespan also prevent aging-related disease in these mice. Translation into human applications poses additional challenges, in particular with regard to safety. Long-term administration of rapa mycin, for instance, might not be feasible as it might cause adverse events owing to its potent immunosuppressive and anti proliferative activities. 90 Alternative small molecules that activate autophagy in mTOR-dependent and mTOR-independent pathways have been identified, including compounds that are already in clinical use. 91 One example is gluco samine, which has a long history of use as a dietary supplement, and which can activate both the UPR and autophagy. [92] [93] [94] [95] In liver cells, UPR activation was related to a change in hexosamine pathway flux, 92 and, interestingly, the induction of autophagy appeared to occur by an mTOR-independent mechanism. 95 
Conclusions
Recent findings on aging-related changes in joint carti lage suggest that cellular homeostasis mechanisms deteriorate with time, setting the stage for structural and mechanical failure of the tissue. Subsequently, cartilage cell death and activation of abnormal gene expression patterns initiates the cartilage remodeling process that ultimately leads to OA pathology and symptoms. Mechanisms such as autophagy, the UPR, or pathways that directly regulate superficial zone cell viability are critical for maintaining cartilage and joint health. Decline in the function of these mechanisms represents the earliest known aging-related changes to articular cartilage.
Autophagy and the UPR are linked to signaling pathways that mediate aging and longevity. It can be hypothesized that the general mechanisms that govern aging of the whole organism also contribute to tissue-specific changes. This hypothesis has been confirmed in agingrelated disease of the brain, muscle, and heart. 79, 80 The general paradigm that emerges is one of homeo stasis failure, which might be triggered by organ-specific factors, but the cellular homeostasis mechanisms that are affected in different organs are the same.
Candidate compounds that modulate homeostasis and longevity pathways have been identified in vitro, and a substantial number have been shown to prolong the lifespan of invertebrates, mice, and other vertebrates. How ever, these compounds have yet to be tested in animal models for their potential to prevent failure of carti lage homeostasis and to decrease the risk of OA development. Animal models are available to test candidate compounds for their effects on general aging phenotypes and tissue-specific pathologies, including several models of spontaneous OA, such as the Hartley guinea pig or STR/ort mice. 96 Translation of measures that enhance joint health and decelerate joint aging from animal models to clinical application will require different approaches to those used in previous clinical trials of pharmaceutical agents with potential disease-modifying activity, which were tested in patients with established or advanced OA. Subsets of individuals can be identified as at risk of develop ing OA, for example on the basis of the presence of risk factors, such as history of joint injury, mal alignment, or age. Conceptually, such patient populations could benefit from interventions that augment mechanisms of homeostasis. The failure of promising pharma ceuticals in clinical trials that enrolled patients with advanced disease supports the notion that reinforcing homeostasis might decrease the severity of OA or the risk of developing OA.
Clinical trials to demonstrate that such interventions reduce the risk of OA development would require longterm observations in large populations. Biomarkers indicative of early stages of cartilage degradation are available, 97 and could be tested in clinical studies in patients at risk of developing early age-related or mechanically-induced changes in cartilage homeostasis.
In conclusion, experience from previous clinical trials indicates that in established OA it is not only impossible to reverse existing damage but also that preventing disease progression is a challenge. OA prevention should be pursued as an alternative approach to constrain the predicted large increase in OA prevalence as the population ages. Aging is recognized as a major risk factor for OA, and mechanisms and molecular targets that could be exploited to delay aging-related functional deterioration of cellular homeostasis have been identified. A concerted effort by investigators from various disciplines is required to apply recent insights into the mechanisms of cartilage homeostasis to the development of effective approaches to decelerating joint aging and reducing OA risk.
Review criteria
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